By Conjoint Professor David goldstein

Conference Papers

GOLDSTEIN D; SIELAFF K; STORER B; SMALLEY RV; BORDEN EC; WITT P; BROWN R; DATTA S, 1988, 'EFFECT OF ROUTE ON BIOLOGICAL RESPONSE MODIFICATION BY INTERFERON BETA-SER', in PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, pp. 184 - 184

Ko A; Reni M; Riess H; Pelzer U; O'Reilly EM; Winter J; Oh DY; Li CP; Tortora G; Chang HM; Lopez CD; Tabernero J; Van Cutsem E; Philip P; Goldstein D; Berlin JD; Ferrara S; Li M; Lu B; Romano A; Marks H; Biankin A; Tempero MA, 'APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, pp. 1464 - 1464

Conference Proceedings (Editor of)

Yang JL; Qu XJ; Russell PJ; Goldstein D, (eds.), 2003, 'Cytokines, Signalling and Diseases 2003', Cairns, Qld, presented at Cytokines, Signalling and Diseases 2003, Cairns, Qld, 26 October 2003 - 30 October 2003

Ngan SY; Fisher R; Burmeister B; Rischin D; Mackay J; Kneebone A; McKendrick J; Goldstein D; McClure B; Joon DL; Joseph D, (eds.), 2002, 'American Society of Clinical Oncology', Orlando, Florida, USA, presented at American Society of Clinical Oncology, Orlando, Florida, USA, 18 May 2002 - 22 May 2002

Conference Posters

Reni M; Riess H; O'Reilly EM; Park JO; Hatoum H; Saez BL; Salminen T; Oettle H; Lopez R; Dowden SD; Karthaus M; Tabernero J; Van Cutsem E; Philip PA; Goldstein D; Berlin J; Tempero MA, 2020, 'Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.', Vol. 38, pp. 4515 - 4515, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.4515

Iioanni L; maharaj A; loughan J; zalcberg J; earnest A; Goldstein D; Kench J; Merrett N; christophi C; croagh D; pilgrim C; burmeister E; white K; neale R; green S; evans S, 2019, 'Prognostic models to predict survival in patients with pancreatic cancer: A systematic review', Bangkok, presented at ASM RACS, Bangkok, 06 May 2019 - 10 May 2019

Wang X; crowe PC; goldstein DG; Yang JY, 2017, 'In vitro and in vivo effect of targeting CDK4/6 and mTOR singly or together in sarcoma cell lines', Adelaide, Australia, presented at 2017 Annual Sarcoma Conference, Adelaide, Australia, 13 October 2017 - 14 October 2017

Wang X; Crowe PC; Goldstein DG; Yang JY, 2017, 'Anti-prolifeative effect of targeting CDK4/6 and mTOR alone or in combination in sarcoma cell lines', Florence, Italy, presented at EACR-AACR-SIC: The Challenges of optimising immuno and targeted therapies: from cancer biology to the clinic, Florence, Italy, 24 June 2017 - 27 June 2017

Wang X; Crowe PJ; Goldstein D; Yang JL, 2015, 'Overcoming resistance of targeted EGFR/panHER monotherapy by inhibition of STAT3 escape pathway in sarcoma', Lorne, Victoria, Australia, Vol. 7, pp. 21496 - 21509, presented at 27th Lorne Cancer Conference 2015, Lorne, Victoria, Australia, 12 February 2015 - 14 February 2015, http://dx.doi.org/10.18632/oncotarget.7452

Lim HJ; Wang X; Goldstein ; Crowe , 2015, 'Targeting the PI3K/PTEN/AKT/mTOR pathway in sarcoma cell lines', Lorne, Victoria, Australia, presented at 27th Lorne Cancer Conference 2015, Lorne, Victoria, Australia, 12 February 2015 - 14 February 2015

Wang X; Goldstein ; Crowe ; Yang , 2014, 'Effect and mechanism of PF299804 alone and in combination with STAT3 inhibitor in human sarcoma cell lines', San Diego, CA, PA, presented at The 105th Annual Meeting of the American Association for Cancer Research 2014, San Diego, CA, PA, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-172

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'Mechanisms of gefitinib alone and in combination therapy in soft tissue sarcoma cell lines', Boston, MA, US, presented at Molecular Targets and Cancer Therapeutics 2013, Boston, MA, US, 19 October 2013 - 23 October 2013

Wang X; Goldstein D; Crowe P; Yang J, 2013, 'STAT3 inhibitor S3I-201 suppresses human osteosarcoma cell growth', Lorne, Victoria, Australia, presented at 25th Lorne Cancer Conference 2013, Lorne, Victoria, Australia, 14 February 2013 - 16 February 2013

Wang X; Goldstein D; Crowe P; Yang J, 2012, 'Treatment of soft tissue sarcoma cells by EGFR and/or STAT3 inhibitors', presented at The 103rd Annual Meeting of AACR 2012, 31 March 2012 - 04 April 2012

Wang X; Goldstein D; Crowe P; Yang J, 2012, 'STAT3-targeted therapy on human soft tissue sarcomas', Lorne, Victoria, Australia, presented at 24th Lorne Cancer Conference 2012, Lorne, Victoria, Australia, 09 February 2012 - 11 February 2012

Conference Presentations

maharaja A; evans S; neale R; Goldstein D; Merrett N; zalcberg J, 2018, 'Patient-Reported Outcome Measures (PROMs) in Pancreatic Cancer: A Systematic Review', presented at ANZGOSA/ANZHPBA conjoint meeting, Weelington New Zealand, 08 October 2018 - 09 October 2018

Meiser B; Zilliacus E; Wong T; Girgis A; Butow P; Hale S; Kissane D; Perry A; Aranda S; Tomkins S; Hodges J; Norris C; Shaw T; Tebble H; Woodland L; Kaur R; Goldstein D, 2015, 'Communication skills training for oncology health care professionals working with culturally and linguistically diverse patients'

Burmeister E; Jordan S; O'Connell D; Vanessa B; David G; Helen G; Monka J; Neil M; David W; Rachel N, 2015, 'Using a Delphi process to determine optimal care for patients with pancreatic cancer', http://dx.doi.org/10.1016/j.pan.2015.05.308

Wang X; Goldstein D; Crowe P; Yang J-L, 2014, 'Effect and mechanism of PF299804 alone and in combination with STAT3 inhibitor in human sarcoma cell lines', presented at 105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2014 - 09 April 2014, http://dx.doi.org/10.1158/1538-7445.AM2014-1723

Girgis A; Webber K; Bennetts BH; Bonaventura A; Boyle F; Koh E; Friedlander M; Segelov E; Goldstein D, 2012, '"This follow-up care would meet my needs, but I would still worry that problems with my health would not be found": A cross-sectional survey of adult cancer survivors', presented at COSA 39th Annual Scientific Meeting

Conference Abstracts

Zaheed M; Grady JP; Murrow B; Douglas B; Carpenter E; Mckay S; Liang S; Taylor N; Lin FP-Y; Goldstein D; Tucker K; Thomas DM; Ballinger ML, 2024, 'Translating potential germline findings from tumour profiling into routine clinical care.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, JAPAN, Yokohama, Vol. 42, pp. 105 - 105, presented at ASCO Breakthrough: A Global Summit for Oncology Innovators, JAPAN, Yokohama, 08 August 2024 - 10 August 2024, http://dx.doi.org/10.1200/JCO.2024.42.23_suppl.105

Joda M; Li T; Timmins H; Goldstein D; Park S, 2024, 'IDENTIFICATION OF AXONAL DEGENERATION IN PACLITAXEL-TREATED PATIENTS UTILISING NEUROPHYSIOLOGICAL AND BLOOD BASED BIOMARKERS', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, CANADA, Montreal, Vol. 29, pp. S177 - S177, presented at Annual Meeting of the Peripheral-Nerve-Society (PNS), CANADA, Montreal, 22 June 2024 - 25 June 2024

Li T; Timmins H; Mahfouz F; Trinh T; Mizrahi D; Horvath L; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan M; Rutherford C; Goldstein D; Park S, 2024, 'IDENTIFYING THE OPTIMAL OUTCOME MEASURE TO ASSESS CHEMOTHERAPY-INDUCED PERIPHERAL NEUROTOXICITY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, CANADA, Montreal, Vol. 29, pp. S178 - S178, presented at Annual Meeting of the Peripheral-Nerve-Society (PNS), CANADA, Montreal, 22 June 2024 - 25 June 2024

Li T; Timmins HC; Mahfouz FM; Mizrahi D; Horvath L; Harrison ML; Grimison PS; Friedlander M; Marx GM; Boyle FM; Wyld D; Henderson R; King T; Baron-Hay SE; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Identifying optimized assessment of nerve damage during chemotherapy', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 42, presented at Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024 - 29 May 2024

Pitiyarachchi O; Lin FP; Spooner A; Sharbeen G; Barker HP; Thornton K; Collignon E; Ballinger ML; Thomas DM; Magenau A; Porazinski S; Raina A; Sjoquist KM; Chantrill LA; Gebski V; Sowmya A; Timpson P; Pajic M; Goldstein D; Phillips PA, 2024, '1513P Impact of symptom and functional burden on survival in pancreatic ductal adenocarcinoma (PDAC)', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S925 - S925, http://dx.doi.org/10.1016/j.annonc.2024.08.1576

Kong BY; Lin FP-Y; Espinoza D; Thavaneswaran S; Meniawy T; Desai J; Harrup R; Selva-Nayagam S; Charakidis M; Cuff K; Sebastian L; Lee CK; Chinchen S; Thomas DM; Ballinger ML; Simes J; Goldstein D, 2024, '636P Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy', in Annals of Oncology, Elsevier BV, Vol. 35, pp. S505 - S505, http://dx.doi.org/10.1016/j.annonc.2024.08.703

Clifford BK; Goldstein D; Au K; McCrary JM; Trinh T; Li T; Al Deleemy M; Mizrahi D; Harris CA; Forster BC; Huynh W; Boyle F; Tang M; Choi V; Grimison P; Kay S; Collier B; Smith AM; Menant J; Park SB, 2024, 'Exercise Rehabilitation for Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 84 - 85

Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB, 2024, 'Patient Reported Measures as the Optimal Assessment of Chemotherapy-Induced Peripheral Neuropathy', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 86 - 86

Treloar A; Choi V; Grimison P; Young J; Mayer K; Robinson L; Mizrahi D; Horvath L; Goldstein D; Park S, 2024, 'Routine Screening for Chemotherapy-Induced Peripheral Neurotoxicity (CIPN): A Feasibility Study of Clinical Implementation', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 61 - 61

Park S; Morrow A; Grimison P; Boyle F; King T; Koczwara B; Harris C; Robinson L; Mendoza-Jones P; Mizrahi D; Pitiyarachchi O; Huynh W; Kiernan M; Grogan P; Goldstein D; Taylor N, 2024, 'Using Health Implementation Strategies to Improve Patient Outcomes via a Clinical Pathway for Chemotherapy-Induced Peripheral Neuropathy Assessment and Management', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 55 - 56

Ke H; Zaheed M; Lin F; Tucker K; Goldstein D; Douglas B; McKay S; Liang S; Ballinger M; Thomas D; Taylor N, 2024, 'Using Health Implementation to Integrate Precision Care - A Preliminary Analysis of a Combined Hereditary-Cancer and Medical-Oncology Clinic', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 20, pp. 22 - 23

Netto KG; Chiang S; Kokkinos J; Haghighi KS; Raina A; Pitiyarachchi O; Youkhana J; Truong Q; Wenholz D; Li X; Laczka O; Kumar N; Wilkinson J; Goldstein D; Sharbeen G; Phillips PA, 2023, 'CRO67 has therapeutic potential against pancreatic tumor cells and cancer associated fibroblasts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, MA, Boston, Vol. 84, presented at AACR Special Conference - Pancreatic Cancer, MA, Boston, 27 September 2023 - 30 September 2023, http://dx.doi.org/10.1158/1538-7445.PANCA2023-B062

Thavaneswaran S; Lin FP-Y; Napier CE; Grady JP; Ballinger ML; Kansara M; Grimison PS; Pavlakis N; Wong MK; Sjoquist KM; Goldstein D; Chantrill LA; Simes J; Thomas DM, 2023, 'Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, Vol. 41, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Hosen SMZ; Xu Z; Mekapogu AR; Perera C; Goldstein D; Pirola R; Wilson J; Buckley BJ; Ranson M; Apte M, 2022, 'Targeted urokinase plasminogen activator inhibition combined with chemotherapy halts primary tumor growth and eliminates metastasis in advanced pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 37, pp. 36 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000852585700069&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022

Lin FP-Y; Thavaneswaran S; Grady JP; Napier CE; Kansara M; Sebastian L; Kee D; Oakes SR; Blackburn J; Scott HS; Glover A; Fox SB; Goldstein D; Leo P; Amanuel B; Desai J; Lee CK; Ballinger ML; Simes J; Thomas DM, 2022, 'Molecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3073 - 3073, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3073

Mizrahi D; Goldstein D; Trinh T; Li T; Timmins HC; Harrison M; Marx GM; Hovey EJ; Lewis CR; Friedlander M; Park SB, 2022, 'Clinical Predictors And Levels Of Physical Activity Among Cancer Survivors Treated With Neurotoxic Chemotherapy', in Medicine & Science in Sports & Exercise, LIPPINCOTT WILLIAMS & WILKINS, San Diego, California, Vol. 54, pp. 322 - 322, presented at ACSM 2022 Annual Meeting & World Congresses, San Diego, California, 31 May 2022 - 04 June 2022, http://dx.doi.org/10.1249/01.mss.0000879060.88938.0b

Mizrahi D; Goldstein D; Kiernan MC; Robinson L; Pitiyarachchi O; McCullough S; Mendoza-Jones P; Grimison P; Boyle F; Park SB, 2022, 'Development and consensus of 'CIPN-path': A clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 190 - 190

Li T; Timmins HC; Trinh T; Mizrahi D; Horvath L; Grimison P; Harrison M; Rutherford C; King M; Kiernan MC; Goldstein D; Park SB, 2021, 'Assessing chemotherapy-induced peripheral neuropathy - A psychometric analysis of current approaches', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 31 - 32, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mekapogu A; Xu Z; Pothula S; Perera C; Pang T; Hosen SMZ; Damalanka V; Mahoney M; Janetka J; Klampfer L; Goldstein D; Pirola R; Wilson J; Apte M, 2021, 'Hepatocyte growth factor/c-MET inhibition plus chemotherapy improves tumor immunity and eliminates metastasis in pancreatic cancer', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 36, pp. 29 - 30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693377800055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hosen SMZ; Haar J; Xu Z; Perera C; Mekapogu AR; Pang TCY; Pothula S; Goldstein D; Pirola R; Wilson J; Buckley BJ; Ranson M; Apte M, 2021, 'Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 36, pp. 25 - 26, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693377800051&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Georgiou CL; Kee D; Caldwell R; Krasovitsky MS; Tay R; Bourne A; Turner M; Goldstein D; Scott C, 2021, 'The Australian rare cancer portal: An innovative online service co-ordinating national expert care for rare cancer patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000680945900014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hosen SMZ; Xu Z; Perera C; Mekapogu AR; Pang TCY; Goldstein D; Pirola RC; Wilson JS; Buckley BJ; Ranson M; Apte MV, 2021, 'Targeting the Urokinase Plasminogen Activator Pathway in Combination With Chemotherapy Inhibits Pancreatic Cancer Progression', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, Vol. 50, pp. 1065 - 1065

Mizrahi D; Park SB; Li T; Timmins H; Trinh T; Au K; Battaglini E; Wyld D; Henderson R; Grimison P; Ke H; Marker J; Wall B; Goldstein D, 2020, 'Haemoglobin, body mass index and age as risk-factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S1371 - S1371, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.328

Pang TCY; Mekapogu AR; Xu Z; Pothula S; Goldstein D; Pirola RC; Wilson JS; Becker TM; Apte MV, 2020, 'Characterization of Circulating Pancreatic Stellate Cells (Pscs) in Pancreatic Cancer, by Single Cell Transcriptomic Analysis', in PANCREAS, LIPPINCOTT WILLIAMS & WILKINS, Vol. 49, pp. 1423 - 1423, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000614149700122&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Perera C; Xu Z; Mekapogu AR; Hosen SMZ; Pothula S; Cohen-Hyams T; Killingsworth M; Greenfield J; Chari S; Goldstein D; Pirola R; Wilson J; Apte M, 2020, 'Effects of pancreatic stellate cell- and cancer cell-derived exosomes on islet cell functions: Implications for pancreatic cancer-related diabetes', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, Vol. 35, pp. 23 - 23, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000589476200030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Best M; Butow P; Jacobs C; Juraskova I; Savard J; Meiser B; Goldstein D; Ballinger M; Bartley N; Napier C; Davies G; Thomas D; Tucker K; Schlub T; Newson AJ, 2020, 'Advanced cancer patient preferences for receiving molecular profiling results', in Psycho Oncology, Vol. 29, pp. 1533 - 1539, http://dx.doi.org/10.1002/pon.5446

Battaglini E; Goldstein D; Park S, 2020, 'Determining the impact of chemotherapy-induced peripheral neuropathy: A survey of cancer survivors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368308496&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Butow P; Davies G; Napier C; Thomas DM; Bartley N; Goldstein D; Ballinger ML; Juraskova I; Schlub TE; Tucker K; Meiser B; Young M-A, 2020, 'Return of results after somatic tumor mutation profiling in advanced cancer: Psychological impacts.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368301063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Battaglini E; Goldstein D; Park S, 2020, 'Chemotherapy-induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-term Quality of Life', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 548 - 548, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK

Back to profile page